New therapeutic targets and agents for osteoporosis. 2010

Serge Rozenberg

UI MeSH Term Description Entries
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D050071 Bone Density Conservation Agents Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. Antiresorptive Agent,Antiresorptive Agents,Antiresorptive Drugs,Bone Resorption Inhibitors,Bone Resorption Inhibitory Agents,Agent, Antiresorptive,Inhibitors, Bone Resorption,Resorption Inhibitors, Bone

Related Publications

Serge Rozenberg
February 2012, La Revue du praticien,
Serge Rozenberg
February 2019, Maturitas,
Serge Rozenberg
March 2023, Purinergic signalling,
Serge Rozenberg
November 2012, Maturitas,
Serge Rozenberg
January 2017, Current pharmaceutical design,
Serge Rozenberg
February 2020, Expert opinion on therapeutic targets,
Serge Rozenberg
December 2012, The New England journal of medicine,
Serge Rozenberg
July 2014, Expert opinion on therapeutic targets,
Serge Rozenberg
April 2020, Medecine sciences : M/S,
Copied contents to your clipboard!